Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing.
Transmucosal immediate-release fentanyl (TIRF) drugs are potent, rapid-acting opioids approved to treat breakthrough pain in patients with cancer who are tolerant to other around-the-clock opioid analgesics. In March 2012, a US Food and Drug Administration–approved [...]